{"filings":[{"id":696523,"accession_number":"0001628280-26-038499","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2026-05-27T20:30:22+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Alnylam elects Benjamin F. Cravatt to board; shareholders re-elect directors and approve say-on-pay","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Benjamin F. Cravatt, Ph.D. elected to Board effective June 1, 2026, filling newly created eleventh seat; term expiring 2028 annual meeting.","Dr. Cravatt receives $75,000 annual cash retainer and initial stock option valued at $600,000 vesting over three years.","At May 20, 2026 annual meeting, shareholders re-elected Class I directors Arbuckle, Greenstreet, and Sigal with over 95% votes for each.","Say-on-pay approved with 111.8M for vs 8.6M against; PwC ratified as auditor with 119.8M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91698,"accession_number":"0001628280-26-028601","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q1 net product revs $1.04B (+121%); GAAP EPS $1.51 vs -$0.14; reaffirms FY26 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Global net product revenues $1,036M, up 121% YoY; total TTR revenues $910M (+153%).","GAAP net income $206M vs loss $18M; GAAP diluted EPS $1.51; non-GAAP EPS $1.99.","Reiterates FY26 combined net product revenue guidance of $4.9B-$5.3B.","AMVUTTRA (vutrisiran) net product revenues $890M; TRITON-CM expanded to ~1,750 patients.","Initiated Phase 1 obesity trial (ALN-2232) and new collaborations with Viz.ai, AHA, Tenaya, Helix."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101952,"accession_number":"0001628280-26-014728","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alnylam grants CEO Greenstreet performance-based PSUs tied to $500-$800 stock price by 2029","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Target of 55,373 PSUs ($18.0M face value at $325.07 close on grant date).","Vesting requires 30-day avg stock price of $500 (50% vest) to $800 (200% vest) by Dec 31, 2029.","Baseline threshold of $500 exceeds all-time high; award forfeited if price below $500.","Special award granted alongside annual equity, designed with independent compensation consultant.","Under Greenstreet, Alnylam achieved ~100% stockholder return, AMVUTTRA approval, and 2025 profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101951,"accession_number":"0001628280-26-007491","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam posts Q4 net product rev $995M (+121%); achieves full-year GAAP profitability","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net product revenue $995M (+121% YoY); full-year $2,987M (+81%); total revenue Q4 $1.1B.","GAAP net income $111.5M ($0.82 diluted EPS) vs. loss a year ago; full-year GAAP net income $313.7M.","Non-GAAP operating income $849.8M for FY2025; company expects sustainable operating income growth.","AMVUTTRA (ATTR-CM) drove TTR franchise: Q4 $827M, full year $2,314M (+103% YoY).","Launches 'Alnylam 2030' strategy; plans $250M manufacturing expansion; board appoints Stuart Arbuckle."],"consensus_eps_estimate":null,"consensus_eps_actual":2.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":3713937000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101950,"accession_number":"0001628280-26-001755","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam reports preliminary 2025 net product revs $2,987M (+81% YoY); guides 2026 revs $4.9B-$5.3B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary 2025 net product revenue $2,987M (81% growth vs 2024); TTR franchise $2,487M (103% growth).","2026 combined net product revenue guidance $4.9B–$5.3B (71% growth at midpoint); TTR guidance $4.4B–$4.7B.","New 'Alnylam 2030' strategy targets 25%+ total revenue CAGR and ~30% non-GAAP operating margin by 2030.","Pipeline goals: nucresiran Phase 3 in ATTR-CM/polyneuropathy; mivelsiran Phase 2 enrollment in H1 2026.","Preliminary Q4 2025: total TTR revs ~$859M (AMVUTTRA $827M, ONPATTRO $32M); total rare revs ~$137M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":3713937000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118284,"accession_number":"0001193125-25-315047","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alnylam repurchases $34.4M of 1.00% convertible notes due 2027 for ~$51.9M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repurchased $34.4M aggregate principal of 1.00% convertible senior notes due 2027 for total cash cost of approximately $51.9M, including accrued interest.","Remaining outstanding principal after repurchases is $362.8M.","Repurchase price is subject to adjustment based on daily VWAP over a measurement period starting December 11, 2025.","Existing capped call transactions entered upon note issuance remain in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118283,"accession_number":"0001628280-25-055084","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alnylam board changes: Bonney and Bertozzi resign; Arbuckle appointed director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mike Bonney and Carolyn Bertozzi resigned from Alnylam board effective Dec 2, 2025; no disagreement with company.","Bertozzi resigned due to election to Eli Lilly board (eff. Dec 8, 2025); will continue as scientific advisor.","Stuart Arbuckle (ex-Vertex COO) elected to board, effective Jan 5, 2026; receives $75K annual cash retainer plus stock.","Board size reduced from 11 to 10 following resignations; Arbuckle serves as Class I director until 2026 annual meeting.","Arbuckle brings commercial and leadership experience from GSK, Amgen, and Vertex; also serves on Rhythm Pharma board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118282,"accession_number":"0001628280-25-047342","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q3 net product rev $851M (+103% YoY); raises 2025 guidance 10% to $2.95-3.05B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenues $851M (+103% YoY); TTR franchise $724M (+135% YoY) led by AMVUTTRA ATTR-CM launch.","GAAP net income $251M ($1.84 diluted EPS) vs loss of $111.6M; non-GAAP net income $396M ($2.90 EPS).","2025 guidance raised: total net product revs $2.95B-$3.05B (10% midpoint increase); TTR rev guidance $2.475B-$2.525B.","Initiated ZENITH Phase 3 for zilebesiran in hypertension and TRITON-PN Phase 3 for nucresiran in hATTR-PN.","Appointed Bryan Supran EVP & Chief Legal Officer; issued $661M convertible notes; received subpoena on government price reporting."],"consensus_eps_estimate":null,"consensus_eps_actual":0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":2616904000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118281,"accession_number":"0001193125-25-230201","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Alnylam enters $500M revolving credit facility maturing 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $500M Revolving Credit Facility includes $150M letter of credit sublimit; available for working capital and general corporate purposes.","Interest rates: Term SOFR plus 1.50%–2.50% (based on Total Leverage Ratio); commitment fee 0.20%–0.35% on unused commitments.","Financial covenants: Total Net Leverage Ratio ≤ 3.75:1.00 and Consolidated Interest Coverage Ratio ≥ 3.00:1.00, tested quarterly.","Maturity September 30, 2030; springing maturity if outstanding Springing Maturity Debt exceeds $630M or 100% of EBITDA.","Guaranteed by material domestic subsidiaries and secured by substantially all assets, subject to customary exceptions and release conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134733,"accession_number":"0001193125-25-202366","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Alnylam issues $661.25M zero-coupon convertible notes due 2028; repurchases $637.8M of existing notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $661.25M aggregate principal of 0.00% Convertible Senior Notes due 2028; initial conversion price $670.11/share (~40% premium).","Capped call transactions entered to offset dilution; cost $35.3M, cap price $837.61/share (~75% premium).","Repurchased $637.8M of existing 1.00% convertible notes due 2027 for ~$1,105.8M total (including accrued interest).","Notes mature Sept 15, 2028, no regular interest; settlement in cash, shares, or combination at Alnylam's election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134732,"accession_number":"0001193125-25-199686","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alnylam prices $575M zero-coupon convertible notes due 2028; repurchases $637.8M of 2027 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$575M principal of 0.00% convertible senior notes due 2028 priced; initial conversion price ~$670.11/share, 40% premium to VWAP.","Net proceeds ~$561.6M; ~$30.7M used for capped call transactions with cap price ~$837.61/share (75% premium).","Concurrently repurchased ~$637.8M of existing 1.00% convertible notes due 2027 for ~$1,105.8M including accrued interest.","Offering upsized from earlier $500M announcement; initial purchasers have option for additional $86.25M.","Closing expected Sept 12, 2025; notes mature Sept 15, 2028; redeemable after Sept 20, 2027 if stock >130% conversion price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134731,"accession_number":"0001178670-25-000089","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q2 net product rev $672M (+64% YoY); TTR franchise $544M (+77%); raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net product revenues $672M, +64% YoY; TTR franchise $544M (+77%) driven by AMVUTTRA sales of $492M.","GAAP loss from operations $16M vs income $49M in Q2 2024; non-GAAP income from operations $95M.","Raised FY2025 guidance: TTR revenue to $2.175-2.275B; total net product revenue to $2.65-2.8B (+27% at midpoint).","~1,400 ATTR-CM patients on AMVUTTRA as of June 30; approvals secured in EU, UK, Brazil, and Japan.","Initiated TRITON-CM Phase 3 trial for nucresiran in ATTR-CM; received FDA Fast Track designation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":1367878000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151638,"accession_number":"0001178670-25-000076","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alnylam promotes Pushkal Garg to Chief R&D Officer; merges R&D functions","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pushkal Garg appointed EVP, Chief Research and Development Officer to lead integrated R&D organization.","Kevin Fitzgerald's role expanded to include external innovation; receives one-time RSU grant of $2.5M.","Garg's base salary set at $825,000 with STI target of 65% of base; LTI target to be determined.","Fitzgerald's STI target increased to 60% of base salary.","Alnylam targets delivering RNAi therapeutics to all major tissues by 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151637,"accession_number":"0001178670-25-000062","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Alnylam shareholders approve officer exculpation charter amendment, re-elect four directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed certificate of amendment to allow officer exculpation; approved with 111.5M for, 7.1M against.","Re-elected four Class III directors (Carolyn Bertozzi, Margaret Hamburg, Colleen Reitan, Amy Schulman) with majority support.","Approved Second Amended and Restated 2018 Stock Incentive Plan (114.0M for, 4.6M against).","Non-binding advisory vote on executive compensation passed (111.7M for, 6.9M against).","Ratified PwC as independent auditors for FY2025 (117.0M for, 6.4M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151636,"accession_number":"0001178670-25-000050","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q1 product rev $469M (+28% YoY); AMVUTTRA approved for ATTR-CM; guides FY25 $2.05-2.25B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenues $594M, up 20% YoY; GAAP operating income $18M vs loss of $43M in Q1 2024.","Q1 global net product revenues $469M, 28% growth YoY; hATTR-PN franchise grew 36%.","AMVUTTRA (vutrisiran) received FDA approval for ATTR-CM; launch underway with early progress.","Qfitlia (fitusiran) approved by FDA for hemophilia A/B, sixth Alnylam-discovered RNAi therapeutic.","Reiterated FY2025 combined net product revenue guidance of $2.05B-$2.25B."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":594189000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170486,"accession_number":"0001178670-25-000038","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alnylam gets FDA approval for AMVUTTRA in ATTR-CM, first RNAi therapy for cardiomyopathy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved AMVUTTRA for ATTR-CM to reduce cardiovascular mortality, hospitalizations, and urgent heart failure visits.","HELIOS-B trial showed 28% risk reduction in all-cause mortality + recurrent CV events; 36% mortality reduction through 42 months overall.","First and only FDA-approved therapy covering both ATTR-CM and hATTR-PN manifestations in adults.","About 150K US patients affected; Alnylam expects $0 out-of-pocket cost for majority under Alnylam Assist program.","Marketing applications under review by EMA, ANVISA, PMDA; further global submissions planned in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170485,"accession_number":"0001178670-25-000031","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alnylam co-founder Dr. Phillip A. Sharp to retire from board effective May 8, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Sharp informed the board on March 3, 2025; retirement is not due to any disagreement.","He will continue to serve on Alnylam's Scientific Advisory Board after retirement.","Dr. Sharp co-founded Alnylam in 2002 and is a Nobel Prize winner for RNA splicing.","The company issued a press release on March 5, 2025 announcing the transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170484,"accession_number":"0001178670-25-000020","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q4 product rev $451M (+30%); FY rev $1.65B (+33%); vutrisiran sNDA PDUFA Mar 23","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 global net product revenues $451M (+30% vs Q4 2023); full year $1,646M (+33%).","Q4 total revenues $593.2M; net loss $83.8M improved from $137.9M loss in Q4 2023.","FDA accepted sNDA for vutrisiran in ATTR cardiomyopathy; PDUFA target date March 23, 2025.","Non-GAAP net income of $8.0M in Q4 vs loss of $96.6M in prior year.","Company reiterates 2025 product sales and profitability guidance; R&D Day Feb 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":2248243000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170483,"accession_number":"0001178670-25-000008","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam reports preliminary FY2024 net product revenues of $1.65B (+33% YoY); guides FY2025 $2.05-2.25B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net product revenues ~$451M; FY2024 ~$1,646M, representing 33% annual growth.","2025 combined net product revenue guidance of $2.05B-$2.25B, 31% growth at mid-point vs 2024.","TTR franchise (ONPATTRO/AMVUTTRA): FY2024 ~$1,223M; 2025 guidance $1.6B-$1.725B (36% growth).","Rare franchise (GIVLAARI/OXLUMO): FY2024 ~$423M; 2025 guidance $450M-$525M (15% growth).","Company expects 2025 non-GAAP operating income profitability; vutrisiran PDUFA date March 23, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":2248243000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187474,"accession_number":"0001178670-24-000052","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q3 product revenue $420M (+34%); GAAP EPS -$0.87, guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Global net product revenues $420M, up 34% YoY; TTR (ONPATTRO+AMVUTTRA) $309M, Rare (GIVLAARI+OXLUMO) $111M.","GAAP net loss $111.6M ($0.87 loss per share) vs. prior-year net income $147.8M ($1.18); Non-GAAP loss $64.2M ($0.50).","Submitted sNDA in U.S. and Type II Variation in EU for vutrisiran in ATTR-CM using Priority Review Voucher; potential U.S. launch early 2025.","Positive Phase 1 mivelsiran data in Alzheimer's: >90% sAPPβ lowering after second dose; no new safety signals. Ph2 planned year-end.","Suspended ALN-KHK development for type 2 diabetes; appointed Robert Hesslein as Chief Legal Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":1655077000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203984,"accession_number":"0001178670-24-000039","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q2 net product rev $410M +34% YoY; HELIOS-B positive; guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Global net product revenue $410M, up 34% YoY; TTR business (ONPATTRO+AMVUTTRA) grew 37% YoY.","HELIOS-B Phase 3 vutrisiran met primary endpoint (28% reduction composite); all-cause mortality reduced 36% in overall population.","GAAP net loss $16.9M; non-GAAP net income $73.8M ($0.58 non-GAAP diluted EPS).","Raised 2024 combined net product revenue guidance from $1.4-1.5B to $1.575-1.65B.","Planned sNDA submission for vutrisiran using Priority Review Voucher; Phase 3 for ALN-TTRsc04 at year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":1154158000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220650,"accession_number":"0001178670-24-000027","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Alnylam shareholders re-elect four Class II directors, approve say-on-pay and auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four Class II nominees (Ausiello, Brandicourt, Kellogg, Pyott) re-elected with >90% of votes cast.","Non-binding advisory vote on executive compensation passed: 106.8M for, 6.1M against.","Ratification of PricewaterhouseCoopers as FY2024 auditor approved: 114.5M for, 3.5M against.","All proposals passed with substantial margins; total shares outstanding 126,452,099.","Terms of eight other directors continued after the meeting; no changes to board composition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220649,"accession_number":"0001178670-24-000021","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q1 net product rev $365M (+32% YoY); net loss narrows to $0.52/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $365M, up 32% YoY; TTR franchise $264M (+29%), Rare $101M (+40%).","GAAP net loss $65.9M ($0.52 per share) vs $174.1M ($1.40) in Q1 2023.","2024 guidance reiterated: combined net product revenue $1.4B–$1.5B.","Zilebesiran: positive KARDIA-2 results; KARDIA-3 initiated, triggering $65M Roche milestone.","HELIOS-B Phase 3 topline results for vutrisiran on track for late June/early July."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":494333000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240277,"accession_number":"0001193125-24-057906","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alnylam announces departure of EVP, Chief Legal Officer Indrani Franchini","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Separation effective March 1, 2024; severance of $597,000 (12 months' base salary) paid bi-weekly.","Lump sum payment for 2023 annual incentive plan bonus, adjusted by corporate multiplier determined by Board.","One-year consulting arrangement through March 2025; continued vesting of unvested equity awards during consulting period.","$500/hour compensation for consulting beyond 10 hours per month; up to $15,000 legal fee reimbursement.","Consulting period; outstanding stock options remain exercisable for 3 months after consulting period; non-compete restrictions waived."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240276,"accession_number":"0001157523-24-000253","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q4 net product rev $346M, FY $1.24B (+39%); FY24 guide $1.4-1.5B; HELIOS-B readout late June/early July","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net product revenue $346M: ONPATTRO $79M, AMVUTTRA $175M, GIVLAARI $59M, OXLUMO $33M.","Full year 2023 net product revenue $1.24B, up 39% YoY; GAAP net loss per share ($3.52); non-GAAP ($1.61).","FY24 guidance: combined net product revenue $1.4B-$1.5B, plus collaboration and royalty revenue; operating expense guidance provided.","HELIOS-B Phase 3 top-line results expected late June or early July; updated statistical analysis plan announced.","FDA cleared Part B of ALN-APP Phase 1 study at doses up to 180 mg every six months; partial clinical hold remains for higher doses."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":1828292000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240275,"accession_number":"0001193125-24-011278","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alnylam EVP & Chief Legal Officer Indrani Franchini to depart March 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Indrani L. Franchini to transition from EVP, Chief Legal Officer and Secretary effective March 1, 2024.","Mutual agreement reached on January 12, 2024; severance terms to be formalized in a written agreement on or before the separation date.","No replacement has been named for the Chief Legal Officer and Secretary role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240274,"accession_number":"0001193125-24-003854","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam prelim 2023 product rev $1.24B (+39% YoY); Q4 growth across all drugs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 global net product revenues $1,241M, up 39% YoY (39% constant currency).","Q4 2023 revenues: ONPATTRO $79M, AMVUTTRA $175M, GIVLAARI $59M, OXLUMO $33M.","Year-end cash & investments ~$2.4B, up from $2.2B at end of 2022.","Over 4,060 patients on ONPATTRO/AMVUTTRA; over 650 on GIVLAARI, over 430 on OXLUMO at year-end 2023.","Management cites strong patient demand and commercial execution; HELIOS-B readout expected early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":1828292000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257778,"accession_number":"0001157523-23-001622","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q3 2023 net product revenues $313M (+35% YoY); FDA CRL for ONPATTRO cardiomyopathy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net product revs $313M (+35% YoY); GAAP net income $147.8M ($1.15 diluted EPS) vs loss of $405.9M in Q3 2022.","FDA issued Complete Response Letter for patisiran (ONPATTRO) sNDA for ATTR cardiomyopathy.","Positive topline results from KARDIA-1 Phase 2 study of zilebesiran in hypertension; entered global collaboration with Roche.","Updated 2023 guidance: collaboration & royalty rev $575-625M; net product rev reiterated at $1,200-1,285M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":1388574000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257777,"accession_number":"0001193125-23-253084","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA rejects Alnylam's patisiran sNDA for ATTR cardiomyopathy; company abandons U.S. expansion","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued Complete Response Letter citing insufficient evidence of clinical meaningfulness for patisiran in cardiomyopathy of ATTR amyloidosis.","No safety, study conduct, drug quality or manufacturing issues; existing ONPATTRO polyneuropathy indication unchanged.","Alnylam will no longer pursue expanded U.S. indication for patisiran; focus shifts to vutrisiran (HELIOS-B Phase 3) and ALN-TTRsc04.","FDA advisory committee had voted 9:3 that benefits outweigh risks, but FDA still issued CRL.","Company to host investor call at 8:30 a.m. ET on Oct 9, 2023 to discuss the CRL."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275128,"accession_number":"0001193125-23-245768","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alnylam director Marsha H. Fanucci resigns; Peter N. Kellogg named Audit Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marsha H. Fanucci resigned from Board effective Sept 29, 2023; no disagreement with company.","Peter N. Kellogg appointed Chair of Audit Committee; qualifies as audit committee financial expert.","Board size reduced from 13 to 12 members effective upon Fanucci's resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275127,"accession_number":"0001193125-23-202313","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Alnylam Q2 net product revenues up 43% to $306M; Vaishnaw steps down as President","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product rev $306M (+43% YoY); GAAP net loss $276M ($2.21/share), non-GAAP net loss $202M ($1.62/share).","AMVUTTRA rev $132M, ONPATTRO $91M, GIVLAARI $58M, OXLUMO $24M; total TTR growth 72% in U.S.","Reiterated 2023 guidance: combined net product rev $1.2B-$1.285B.","U.S. Attorney's Office closed ONPATTRO marketing investigation with no action.","President Akshay Vaishnaw transitions to part-time Chief Innovation Officer, effective Oct 2, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":638044000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275126,"accession_number":"0001193125-23-194715","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Alnylam partners with Roche on zilebesiran; receives $310M upfront, up to $2.5B milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash payment of $310 million; potential total deal value up to $2.8 billion including development, regulatory, and sales milestones.","Alnylam and Roche to co-develop and co-commercialize zilebesiran in US (50/50 profit share); Roche gets exclusive ex-US rights with low double-digit royalties.","Alnylam leads joint clinical development plan including cardiovascular outcomes trial; development costs split 40% Alnylam, 60% Roche.","Zilebesiran is an investigational RNAi therapeutic for hypertension, currently in Phase 2; Phase 1 showed durable blood pressure reduction up to 6 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292538,"accession_number":"0001193125-23-179631","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alnylam announces FDA advisory committee meeting for ONPATTRO in ATTR cardiomyopathy on Sept 13, 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Advisory Committee (Cardiovascular and Renal Drugs) to review sNDA for patisiran in cardiomyopathy of ATTR amyloidosis on Sept 13, 2023.","PDUFA action date set for October 8, 2023.","ONPATTRO currently approved for polyneuropathy of hATTR amyloidosis; sNDA aims to expand label to cardiomyopathy.","Safety and efficacy for cardiomyopathy indication have not yet been established by FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292537,"accession_number":"0001193125-23-151845","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2023-05-23T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Alnylam shareholders re-elect four Class I directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Michael Bonney re-elected with 101.9M for vs 11.8M against; Yvonne Greenstreet 112.4M for vs 1.3M against.","Phillip Sharp re-elected 101.4M for vs 12.3M against; Elliott Sigal 110.1M for vs 3.6M against.","Say-on-pay approved: 109.7M for, 4.0M against; 1-year frequency recommended with 113.5M votes.","PricewaterhouseCoopers ratified as independent auditor for FY2023: 116.1M for, 1.8M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292536,"accession_number":"0001157523-23-000728","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q1 product rev $276M (+48% YoY); ALN-APP CNS data positive; FY guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net product revenue $276M (+48% YoY); AMVUTTRA $102M and ONPATTRO $102M drove TTR growth of 49%.","GAAP net loss $174M ($1.40/share); non-GAAP net loss $132M ($1.06/share). FY23 revenue guidance $1.2B-$1.285B reaffirmed.","Positive interim Phase 1 data for ALN-APP in early-onset Alzheimer's: first human RNAi CNS gene silencing demonstrated.","18-month APOLLO-B data submitted to FDA for ONPATTRO in cardiomyopathy; KARDIA-1 (zilebesiran) topline expected mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":319290000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313208,"accession_number":"0001193125-23-064580","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alnylam expands board to 13, elects Peter N. Kellogg as Class II director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 12 to 13 directors; Kellogg fills new vacancy effective March 7, 2023.","Kellogg will serve as Class II director until 2024 annual meeting and is expected to join the Audit Committee.","Non-employee director cash fee $55,000 (rising to $60,000 April 1, 2023); stock option for 4,948 shares at $194.34 strike.","Option vests ratably over three years; annual equity awards begin 2024 with $400,000 grant-date value.","Indemnification agreement entered with the Company consistent with other non-employee directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313207,"accession_number":"0001157523-23-000344","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q4 2022 product revenue $262M (+35% YoY); guides 2023 revenue $1.2-1.285B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net product revenue $262M; full year $894M (+35% YoY). GAAP net loss $1.13B for 2022 vs $853M in 2021.","ONPATTRO Q4 rev $122M, AMVUTTRA $69M; total TTR rev $651M for 2022 (+37% YoY).","sNDA for ONPATTRO in ATTR cardiomyopathy accepted by FDA; PDUFA date Oct 8, 2023; advisory committee planned.","2023 guidance: combined net product revenue $1.2B-$1.285B; collaboration and royalty revenue also guided.","Cash $2.19B at year-end; appointed Carolyn Bertozzi to board; Amy Schulman becomes Chair."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":1037418000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313206,"accession_number":"0001193125-23-004109","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam reports preliminary FY2022 net product revenue of $894M, up 35% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ONPATTRO: Q4 $122M, FY $558M; AMVUTTRA: Q4 $69M, FY $94M; combined TTR revenue grew 37% YoY.","GIVLAARI: Q4 $47M, FY $173M (+35% YoY); OXLUMO: Q4 $24M, FY $70M (+17% YoY).","Year-end cash and marketable securities ~$2.2B, down from $2.4B at end 2021.","Over 2,975 patients on commercial TTR drugs and over 520 on GIVLAARI; 280 on OXLUMO as of year-end.","Management cites strong AMVUTTRA launch and reiterates Alnylam P5x25 strategic goals."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":1037418000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313205,"accession_number":"0001193125-23-003554","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2023-01-06T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Alnylam appoints Nobel laureate Carolyn Bertozzi to board; Amy Schulman becomes Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carolyn Bertozzi, Ph.D., Nobel laureate in chemistry, elected to Board effective Jan. 5, 2023.","Bertozzi receives $55,000 annual cash retainer and option for 4,268 shares at $225.68.","Michael W. Bonney steps down as Executive Chair, continues as non-independent director.","Lead Independent Director Amy W. Schulman appointed Chair of the Board.","Board expands from 11 to 12 directors; Bertozzi to serve as Class III director until 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331726,"accession_number":"0001157523-22-001411","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q3 net product revenue $232M (+39% YoY); AMVUTTRA Q3 sales $25M; reiterates FY product revenue guide $870-930M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2022 GAAP net loss $405.9M ($3.32/sh) vs $204.5M ($1.72/sh) YoY; non-GAAP net loss $193.4M ($1.58/sh) vs $189.8M ($1.59/sh).","Combined net product revenue $232M: TTR $170M (ONPATTRO $145M, AMVUTTRA $25M), GIVLAARI $46M, OXLUMO $16M.","Reiterated FY 2022 product revenue guidance $870-$930M; lowered collaboration/royalty guidance to $100-$150M from $175-$225M.","AMVUTTRA U.S. launch strong: $25M net rev in first full quarter, 475 Start Forms, 46% new patients, 54% switches from ONPATTRO.","Positive APOLLO-B Phase 3 results for patisiran in ATTR cardiomyopathy; sNDA submission on track for late 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":702383000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349221,"accession_number":"0001193125-22-246487","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2022-09-16T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","9.01"],"status":"ready","headline":"Alnylam closes $1.035B convertible note offering; repays $762M credit facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.035B aggregate principal of 1.00% Convertible Senior Notes due 2027 (initial $900M plus $135M additional).","Conversion rate initially 3.4941 shares per $1,000 principal; conversion price ~$286.20/share, a 35% premium over $212 closing.","Entered capped call transactions with cap price $424/share; cost ~$118.6M to reduce dilution upon conversion.","Used ~$762M of proceeds to repay and terminate April 2020 credit agreement.","Notes mature Sept 15, 2027; interest payable semiannually at 1.00%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349220,"accession_number":"0001193125-22-243702","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2022-09-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alnylam prices $900M convertible senior notes at 1.00% due 2027; conversion premium 35%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $900M (greenshoe up to $135M); interest 1.00% semi-annual; maturity Sept 15, 2027.","Initial conversion price ~$286.20/share, 35% premium over $212.00 close on Sept 12, 2022.","Net proceeds est. $883.2M (or $1,015.8M with greenshoe); $762M to repay credit facility, $103.1M for capped call.","Capped call cap price $424.00/share, reducing dilution upon conversion; counterparties may hedge in open market.","Offering expected to close Sept 15, 2022, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349219,"accession_number":"0001193125-22-228534","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2022-08-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alnylam elects Dr. Elliott Sigal to Board, expanding size to 11 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Sigal elected as Class I director effective Aug 22, 2022; term expires at 2023 annual meeting.","Annual cash fee of $55,000 for non-employee director service.","Initial stock option for 4,456 shares at $217.91/share, $600K grant-date value, vesting over 3 years.","Eligible for annual option award of $400K grant-date value beginning in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349218,"accession_number":"0001157523-22-000945","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q2 product revenue $214M (+33%); AMVUTTRA FDA approved; guidance reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net product revenues $214M: ONPATTRO $153M, GIVLAARI $45M, OXLUMO $15M, up 33% YoY.","FDA approved AMVUTTRA (vutrisiran) for hATTR polyneuropathy; 133 start forms in first weeks.","GAAP net loss $277M ($2.29/share) vs $190M loss year ago; non-GAAP loss $246M ($2.03).","Reiterated FY2022 guidance: combined product revenue $870-$930M, R&D+SG&A $1.62-$1.70B.","Expects APOLLO-B topline results within 3 weeks; cash $2.11B."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":438077000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366115,"accession_number":"0001193125-22-173444","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alnylam gets FDA approval for AMVUTTRA (vutrisiran) for hATTR amyloidosis polyneuropathy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approval based on HELIOS-A Phase 3: 17.0-point mean improvement in mNIS+7 vs placebo (p<0.0001); 50% of patients saw improvement.","AMVUTTRA is first FDA-approved treatment for hATTR polyneuropathy with reversal of impairment; subcutaneous injection once every three months.","Launch expected early July; value-based agreements to accelerate patient access.","Under review by EMA, ANVISA, PMDA; HELIOS-B trial for cardiomyopathy ongoing.","Most common adverse reactions: arthralgia (11%), dyspnea (7%), vitamin A decreased (7%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366114,"accession_number":"0001193125-22-157503","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2022-05-23T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Alnylam stockholders re-elect three Class III directors at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Margaret A. Hamburg, Colleen F. Reitan, Amy W. Schulman re-elected as Class III directors.","Stockholders approved amendment to 2018 Stock Incentive Plan with 93.4M for, 12.4M against.","Non-binding advisory vote on executive compensation passed with 95.3M for, 10.5M against.","PricewaterhouseCoopers ratified as independent auditor for FY 2022 with 109.7M for, 0.6M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366113,"accession_number":"0001157523-22-000494","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alnylam Q1 product revenue $187M, GAAP loss $240M; lowers 2022 guidance to $870-930M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total net product revenue $187M (+38% YoY); GAAP net loss $240M ($2.00 EPS), non-GAAP loss $180M ($1.49 EPS).","Lowered 2022 combined revenue guidance to $870-930M from $900M-$1B due to Q1 pandemic impact and non-recurring Q4 2021 benefits.","FDA extended vutrisiran NDA review to July 14, 2022; company expects launch upon approval if cleared.","Patient growth: ONPATTRO >2,200 (+7%), GIVLAARI >400 (+14%), OXLUMO >160 (+14%) QoQ.","Initiated Phase 1 for ALN-APP (Alzheimer's) and ALN-XDH (gout); filed patent suits against Pfizer/Moderna for COVID-19 vaccine lipids."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":213259000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366112,"accession_number":"0001193125-22-096176","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2022-04-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Steven Paul, M.D. to retire from Alnylam Board effective April 16, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Paul resigns from Board effective April 16, 2022; no disagreement with company operations.","Board size reduced from 11 to 10 members upon Dr. Paul's departure.","Colleen F. Reitan joins PC&C Committee; Amy W. Schulman remains Chair.","Dr. Paul served on Alnylam Board since September 2010; praised for decade of service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366111,"accession_number":"0001193125-22-094409","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2022-04-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alnylam's vutrisiran PDUFA delayed 3 months to July 14, 2022 on packaging facility issue","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA extended review to July 14, 2022 due to amendment addressing inspection classification at third-party packaging/labeling facility.","New secondary packaging and labeling facility identified and submitted to FDA; no inspection observations directly related to vutrisiran.","No additional clinical data requested by FDA; vutrisiran under concurrent review by EMA, ANVISA, and PMDA.","Alnylam aims to minimize impact on other regulatory reviews through timely resolution or alternative facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385605,"accession_number":"0001193125-22-077831","cik":1178670,"company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","form_type":"8-K","filed_at":"2022-03-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Alnylam files patent infringement lawsuits against Pfizer and Moderna over mRNA COVID-19 vaccine lipids","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed lawsuits in U.S. District Court for Delaware against Pfizer and Moderna.","Patent No. 11,246,933 covers biodegradable cationic lipids used in mRNA COVID-19 vaccines.","Seeking damages for infringement including a reasonable royalty; no injunction sought.","Alnylam asserts its patented lipids are foundational to the vaccines and used without license."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":40438956414.8828,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-17T23:59:59+00:00|385605"}